These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 38399429)

  • 1. A Review of Current and Pipeline Drugs for Treatment of Melanoma.
    Natarelli N; Aleman SJ; Mark IM; Tran JT; Kwak S; Botto E; Aflatooni S; Diaz MJ; Lipner SR
    Pharmaceuticals (Basel); 2024 Feb; 17(2):. PubMed ID: 38399429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
    Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
    Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma.
    Lelliott EJ; McArthur GA; Oliaro J; Sheppard KE
    Front Immunol; 2021; 12():661737. PubMed ID: 34025662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral Immunotherapy-Update 2019.
    Hamid O; Ismail R; Puzanov I
    Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.
    Chesney J; Lewis KD; Kluger H; Hamid O; Whitman E; Thomas S; Wermke M; Cusnir M; Domingo-Musibay E; Phan GQ; Kirkwood JM; Hassel JC; Orloff M; Larkin J; Weber J; Furness AJS; Khushalani NI; Medina T; Egger ME; Graf Finckenstein F; Jagasia M; Hari P; Sulur G; Shi W; Wu X; Sarnaik A
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanoma.
    da Silveira Nogueira Lima JP; Georgieva M; Haaland B; de Lima Lopes G
    Cancer Med; 2017 Jun; 6(6):1143-1153. PubMed ID: 28463413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and future roles of targeted therapy and immunotherapy in advanced melanoma.
    Olszanski AJ
    J Manag Care Spec Pharm; 2014 Apr; 20(4):346-56. PubMed ID: 24684639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.
    Devji T; Levine O; Neupane B; Beyene J; Xie F
    JAMA Oncol; 2017 Mar; 3(3):366-373. PubMed ID: 27787543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging Strategies in Systemic Therapy for the Treatment of Melanoma.
    Ascierto PA; Flaherty K; Goff S
    Am Soc Clin Oncol Educ Book; 2018 May; 38():751-758. PubMed ID: 30231371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation.
    Bommareddy PK; Aspromonte S; Zloza A; Rabkin SD; Kaufman HL
    Sci Transl Med; 2018 Dec; 10(471):. PubMed ID: 30541787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advancements in Melanoma Therapies: From Surgery to Immunotherapy.
    Shajari N; Baradaran B; Tohidkia MR; Nasiri H; Sepehri M; Setayesh S; Aghebati-Maleki L
    Curr Treat Options Oncol; 2024 Aug; 25(8):1073-1088. PubMed ID: 39066854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
    Pennock GK; Chow LQ
    Oncologist; 2015 Jul; 20(7):812-22. PubMed ID: 26069281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Advancements in Cell-Based Therapies in Melanoma.
    Nassief G; Anaeme A; Moussa K; Mansour AN; Ansstas G
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
    Kelley MC
    Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Therapy and Immunotherapy for Melanoma in Japan.
    Namikawa K; Yamazaki N
    Curr Treat Options Oncol; 2019 Jan; 20(1):7. PubMed ID: 30675668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.
    Sarnaik AA; Hamid O; Khushalani NI; Lewis KD; Medina T; Kluger HM; Thomas SS; Domingo-Musibay E; Pavlick AC; Whitman ED; Martin-Algarra S; Corrie P; Curti BD; Oláh J; Lutzky J; Weber JS; Larkin JMG; Shi W; Takamura T; Jagasia M; Qin H; Wu X; Chartier C; Graf Finckenstein F; Fardis M; Kirkwood JM; Chesney JA
    J Clin Oncol; 2021 Aug; 39(24):2656-2666. PubMed ID: 33979178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Therapeutic Approaches for Conjunctival Melanoma-What We Know So Far and Where Therapy Is Potentially Heading: Focus on Lymphatic Vessels and Dendritic Cells.
    Peil J; Bock F; Kiefer F; Schmidt R; Heindl LM; Cursiefen C; Schlereth SL
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Status of Biological Therapies for the Treatment of Metastatic Melanoma.
    Tang T; Eldabaje R; Yang L
    Anticancer Res; 2016 Jul; 36(7):3229-41. PubMed ID: 27354579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.